Equities

Emmaus Life Sciences Inc

EMMA:QXR

Emmaus Life Sciences Inc

Actions
  • Price (USD)0.092
  • Today's Change0.000 / -0.07%
  • Shares traded850.00
  • 1 Year change-71.24%
  • Beta1.6593
Data delayed at least 15 minutes, as of May 31 2024 14:42 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, marketing, and sale of treatments and therapies, primarily for rare and orphan diseases. The Company’s lead product, Endari (prescription-grade L-glutamine oral powder), helps to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients aged five years and older. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003, and ELS002. The Company, through Kainos Medicine, Inc. (Kainos), has a license in the territory encompassing the United States, the United Kingdom, and the European Union to patent rights, know-how, and other intellectual property relating to Kainos’s IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, including leukemia, lymphoma, and solid tumor cancers. It has also developed chondrocyte and osteoblast cell sheets using human mesenchymal stem cells.

  • Revenue in USD (TTM)28.46m
  • Net income in USD-4.74m
  • Incorporated1987
  • Employees55.00
  • Location
    Emmaus Life Sciences Inc21250 HAWTHORNE BOULEVARD, SUITE 800TORRANCE 90503United StatesUSA
  • Phone+1 (310) 214-0065
  • Fax+1 (310) 214-0075
  • Websitehttps://www.emmausmedical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
China Pharma Holdings Inc6.42m-3.56m4.70m231.00--0.5287--0.7314-0.8352-0.83521.030.55960.38281.9314.1427,795.89-21.22-29.66-44.77-55.25-11.676.47-55.42-73.090.2523-11.340.261---13.48-10.6822.50---25.78--
Pineapple Inc157.59k376.69k4.75m--0.5834--12.4730.150.11140.11140.0028-0.03180.0388------9.28--53.43---412.55--239.03--0.00-----------611.10------
NS Wind Down Co Inc162.47m-166.43m4.81m703.00------0.0296-3.53-3.533.44-1.050.49362.074.30231,113.80-50.56-30.01-62.82-34.6635.7257.14-102.44-80.872.02-70.171.29---12.282.06-38.43--40.03--
Lipella Pharmaceuticals Inc477.45k-4.74m4.88m5.00--1.76--10.23-0.7633-0.76330.07470.36380.1232--6.2595,490.00-122.37---146.33-------993.39------0.00--144.15---77.81------
Sonnet Biotherapeutics Holdings Inc92.74k-8.43m4.89m12.00--1.60--52.69-5.28-5.280.03150.98130.0097--0.22487,728.33-87.68---194.11-------9,086.22-----138.210.00---57.76--36.64------
Emmaus Life Sciences Inc28.46m-4.74m4.94m55.00------0.1735-0.0931-0.09310.3905-0.67730.63490.81849.36517,454.50-10.58------93.69---16.66--0.12490.1426-----10.77--33.37------
Soligenix Inc699.21k-7.01m4.98m13.00--4.31--7.12-0.7395-0.73950.07250.0730.073--4.1753,785.38-73.17-75.40-2,448.34-154.329.4622.83-1,002.55-620.02----0.7959---11.54-30.6755.50------
ProtoKinetix, Inc.0.00-400.47k5.01m0.00--12.63-----0.0012-0.00120.000.00110.00-------88.14-696.88-101.62-785.51------------0.00------78.22--10.78--
GB Sciences Inc0.00-4.03m5.08m3.00---------0.0105-0.01050.00-0.01190.00----0.00-255.86-49.16---131.40--6.03---995.19---8.63---------2,715.25---60.82--
Stemtech Corp4.64m-4.08m5.09m45.00------1.10-0.0624-0.06240.0619-0.00921.098.3565.16103,098.40-96.70------76.09---88.58--0.1045-1.812.27--------------
Mystic Holdings Inc-100.00bn-100.00bn5.10m79.00--0.2093----------0.2155------------------------0.2228--0.1849--199.82--34.32------
CeCors Inc-100.00bn-100.00bn5.11m6.00---------------0.0163------------------------------------22.70------
Helix BioMedix, Inc.2.07m-2.58m5.23m8.00--3.35--2.53-15.60-15.6012.486.950.80471.874.55258,238.80-100.64-146.31-120.73-173.5768.9630.80-125.06-527.121.69-14.570.00--122.0792.8067.73---29.08--
Biofrontera Inc33.25m-23.09m5.24m85.00------0.1577-12.47-12.4716.84-0.36270.99952.505.75391,200.00-69.40---144.06--48.99---69.44--0.944-3.554.63--18.82---3,045.47------
Data as of May 31 2024. Currency figures normalised to Emmaus Life Sciences Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.